A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease
Latest Information Update: 14 Nov 2025
At a glance
- Drugs Lifitegrast/perfluorohexyloctane (Primary) ; Lifitegrast; Perfluorohexyloctane
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Bausch & Lomb
Most Recent Events
- 22 Aug 2025 New trial record